Historical Valuation
Cytek Biosciences Inc (CTKB) is now in the Fair zone, suggesting that its current forward PS ratio of 3.06 is considered Fairly compared with the five-year average of 79.65. The fair price of Cytek Biosciences Inc (CTKB) is between 2.82 to 17.48 according to relative valuation methord.
Relative Value
Fair Zone
2.82-17.48
Current Price：5.45
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cytek Biosciences Inc (CTKB) has a current Price-to-Book (P/B) ratio of 1.66. Compared to its 3-year average P/B ratio of 2.09 , the current P/B ratio is approximately -20.37% higher. Relative to its 5-year average P/B ratio of -0.15, the current P/B ratio is about -1221.59% higher. Cytek Biosciences Inc (CTKB) has a Forward Free Cash Flow (FCF) yield of approximately -0.94%. Compared to its 3-year average FCF yield of 0.75%, the current FCF yield is approximately -224.40% lower. Relative to its 5-year average FCF yield of 0.42% , the current FCF yield is about -322.72% lower.
P/B
Median3y
2.09
Median5y
-0.15
FCF Yield
Median3y
0.75
Median5y
0.42
Competitors Valuation Multiple
AI Analysis for CTKB
The average P/S ratio for CTKB competitors is 1.35, providing a benchmark for relative valuation. Cytek Biosciences Inc Corp (CTKB.O) exhibits a P/S ratio of 3.06, which is 126.41% above the industry average. Given its robust revenue growth of 1.54%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CTKB
1Y
3Y
5Y
Market capitalization of CTKB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CTKB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CTKB currently overvalued or undervalued?
Cytek Biosciences Inc (CTKB) is now in the Fair zone, suggesting that its current forward PS ratio of 3.06 is considered Fairly compared with the five-year average of 79.65. The fair price of Cytek Biosciences Inc (CTKB) is between 2.82 to 17.48 according to relative valuation methord.
What is Cytek Biosciences Inc (CTKB) fair value?
CTKB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cytek Biosciences Inc (CTKB) is between 2.82 to 17.48 according to relative valuation methord.
How does CTKB's valuation metrics compare to the industry average?
The average P/S ratio for CTKB's competitors is 1.35, providing a benchmark for relative valuation. Cytek Biosciences Inc Corp (CTKB) exhibits a P/S ratio of 3.06, which is 126.41% above the industry average. Given its robust revenue growth of 1.54%, this premium appears unsustainable.
What is the current P/B ratio for Cytek Biosciences Inc (CTKB) as of Jan 11 2026?
As of Jan 11 2026, Cytek Biosciences Inc (CTKB) has a P/B ratio of 1.66. This indicates that the market values CTKB at 1.66 times its book value.
What is the current FCF Yield for Cytek Biosciences Inc (CTKB) as of Jan 11 2026?
As of Jan 11 2026, Cytek Biosciences Inc (CTKB) has a FCF Yield of -0.94%. This means that for every dollar of Cytek Biosciences Inc’s market capitalization, the company generates -0.94 cents in free cash flow.
What is the current Forward P/E ratio for Cytek Biosciences Inc (CTKB) as of Jan 11 2026?
As of Jan 11 2026, Cytek Biosciences Inc (CTKB) has a Forward P/E ratio of -164.00. This means the market is willing to pay $-164.00 for every dollar of Cytek Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cytek Biosciences Inc (CTKB) as of Jan 11 2026?
As of Jan 11 2026, Cytek Biosciences Inc (CTKB) has a Forward P/S ratio of 3.06. This means the market is valuing CTKB at $3.06 for every dollar of expected revenue over the next 12 months.